Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erenumab for Acute Post-Traumatic Headache
NCT05049057Phase 2Recruiting
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Start
- Jul 2022
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of erenumab in post-traumatic headache (PTH) (2 arms), sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine. Primary endpoint: Monthly Headache Days. Started Jul 2022; status: recruiting.
02
Drugs
erenumab
03
Conditions
post-traumatic headache (PTH)
Beyond the preview
Go deeper on NCT05049057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05049057.